C4 THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
C4 THERAPEUTICS INC. - More news...
C4 THERAPEUTICS INC. - More news...
- C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum
- C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024
- C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024
- C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins
- C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
- C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines
- C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals
- C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma
- C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)
- C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma
- C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment
- C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
- C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple Myeloma and Non-Hodgkin’s Lymphoma
- C4 Therapeutics Announces Chief Financial Officer Succession
- C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
- C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer
- C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer
- C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC
- C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
- C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days
- C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
- C4 Therapeutics to Present at Two Virtual February 2023 Conferences
- C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors
- C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
- C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
- C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers
- C4 Therapeutics to Present at Bank of America Securities Precision Oncology Conference 2022
